tiprankstipranks

Myriad Genetics’ portfolio elevated by updated NCCN prostate cancer guidelines

Myriad Genetics (MYGN) commends the updated Prostate Cancer Guidelines from the National Comprehensive Cancer Network, NCCN, as the guidelines underscore the critical role of the company’s portfolio of offerings across the patient’s prostate cancer journey. These guidelines further validate Myriad’s ability to streamline the diagnostic process and enhance personalized treatment options.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue